Research programme: oxazolidinone antibacterials - Johnson & Johnson

Drug Profile

Research programme: oxazolidinone antibacterials - Johnson & Johnson

Alternative Names: JNJ 10283104; JNJ 10391849; RWJ-416457

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Oxazolidinones
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
  • 28 Oct 2008 Antimicrobial data from a preclinical trial presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008)
  • 23 Apr 2007 Preclinical data added to the Bacterial Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top